REGN - Generex Sees Way Forward With Long-Lasting Covid-19 Vaccine

November, 02 2020 01:12 PM Regeneron Pharmaceuticals Inc.

Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective.
GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, South Africa, China, and Canada.
Three trials of its vaccine are in the offing - U.S. (for Malaysia), China, and Canada - all at the expense of the contracting party.
As contracts are announced, fees are collected, and the vaccine subsidiary NGIO, is listed, the stock price will move upwards.

For further details see:

Company Name:	Regeneron Pharmaceuticals Inc.
Stock Symbol:	REGN
Market:	NASDAQ
Website:	regeneron.com